These findings align with recent case reports indicating that ANGPTL3 lowering with Evinacumab protects against atherosclerosis progression in HoFH patients.11,12 A recent and similar UK Biobank study examining the impact of protein-truncating ANGPTL3 variants on CAD found no association.57 Compared to their analysis, key differences were a broader case definition, a stricter definition of controls, and the meta-analysis, which incorporated evidence from previous studies. Here, ANGPTL3 is linked to coronary artery disorder.